Cargando…
Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis
BACKGROUND: Functional liver reserve is an important determinant of survival in cirrhosis. The traditional indocyanine green test (ICG) is cumbersome. Hence, we developed and validated a novel liver imaging, a hybrid of SPECT and CT (Q-SPECT/CT), for evaluating disease severity, outcomes, and respon...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073445/ https://www.ncbi.nlm.nih.gov/pubmed/37035316 http://dx.doi.org/10.3389/fmed.2023.1118531 |
_version_ | 1785019566996324352 |
---|---|
author | Kaur, Amritjyot Verma, Nipun Singh, Baljinder Kumar, Ajay Kumari, Sunita De, Arka Sharma, Ratti Ram Singh, Virendra |
author_facet | Kaur, Amritjyot Verma, Nipun Singh, Baljinder Kumar, Ajay Kumari, Sunita De, Arka Sharma, Ratti Ram Singh, Virendra |
author_sort | Kaur, Amritjyot |
collection | PubMed |
description | BACKGROUND: Functional liver reserve is an important determinant of survival in cirrhosis. The traditional indocyanine green test (ICG) is cumbersome. Hence, we developed and validated a novel liver imaging, a hybrid of SPECT and CT (Q-SPECT/CT), for evaluating disease severity, outcomes, and response to treatment in decompensated cirrhosis (DC). METHODS: We recruited a cohort of DC patients at a tertiary institute between 2016–2019. First, we standardized the Q-SPECT/CT across a predefined range of volumes through phantom experiments. Then we performed clinical and laboratory evaluations, ICG test (retention at 15 min), and Q-SPECT/CT at baseline and 12 months of granulocyte colony-stimulating factor (G-CSF) and standard medical treatment (SMT). RESULTS: In 109 DC patients, 87.1% males, aged 51 ± 10 years, MELD: 14 (7–21), the percent quantitative liver uptake (%QLU) on Q-SPECT/CT exhibited a strong correlation with CTP (r = −0.728, p < 0.001), MELD (r = −0.743; p < 0.001) and ICG-R-15 (r = −0.720, p < 0.001) at baseline. %QLU had the maximum discrimination (AUC: 0.890–0.920), sensitivity (88.9–90.3%), specificity (81.2–90.7%), and accuracy (85.8–89.4%) than liver volumes on Q-SPECT/CT or ICG test for classifying patients in CTP/MELD based prognostic categories. A significant increase in %QLU (26.09 ± 10.06 to 31.2 ± 12.19, p = 0.001) and improvement in CTP/MELD correlated with better survival of G-CSF treated DC patients (p < 0.05). SMT did not show any improvement in Q-SPECT/CT or clinical severity scores (p > 0.05). %QLU > 25 (adj.H.R.: 0.234, p = 0.003) and G-CSF treatment (adj.H.R.: 0.414, p = 0.009) were independent predictors of better 12-months survival in DC. CONCLUSION: Q-SPECT/CT (%QLU) is a novel non-invasive, diagnostic, prognostic, and theragnostic marker of liver reserve and its functions in cirrhosis patients. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT02451033 and NCT03415698. |
format | Online Article Text |
id | pubmed-10073445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100734452023-04-06 Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis Kaur, Amritjyot Verma, Nipun Singh, Baljinder Kumar, Ajay Kumari, Sunita De, Arka Sharma, Ratti Ram Singh, Virendra Front Med (Lausanne) Medicine BACKGROUND: Functional liver reserve is an important determinant of survival in cirrhosis. The traditional indocyanine green test (ICG) is cumbersome. Hence, we developed and validated a novel liver imaging, a hybrid of SPECT and CT (Q-SPECT/CT), for evaluating disease severity, outcomes, and response to treatment in decompensated cirrhosis (DC). METHODS: We recruited a cohort of DC patients at a tertiary institute between 2016–2019. First, we standardized the Q-SPECT/CT across a predefined range of volumes through phantom experiments. Then we performed clinical and laboratory evaluations, ICG test (retention at 15 min), and Q-SPECT/CT at baseline and 12 months of granulocyte colony-stimulating factor (G-CSF) and standard medical treatment (SMT). RESULTS: In 109 DC patients, 87.1% males, aged 51 ± 10 years, MELD: 14 (7–21), the percent quantitative liver uptake (%QLU) on Q-SPECT/CT exhibited a strong correlation with CTP (r = −0.728, p < 0.001), MELD (r = −0.743; p < 0.001) and ICG-R-15 (r = −0.720, p < 0.001) at baseline. %QLU had the maximum discrimination (AUC: 0.890–0.920), sensitivity (88.9–90.3%), specificity (81.2–90.7%), and accuracy (85.8–89.4%) than liver volumes on Q-SPECT/CT or ICG test for classifying patients in CTP/MELD based prognostic categories. A significant increase in %QLU (26.09 ± 10.06 to 31.2 ± 12.19, p = 0.001) and improvement in CTP/MELD correlated with better survival of G-CSF treated DC patients (p < 0.05). SMT did not show any improvement in Q-SPECT/CT or clinical severity scores (p > 0.05). %QLU > 25 (adj.H.R.: 0.234, p = 0.003) and G-CSF treatment (adj.H.R.: 0.414, p = 0.009) were independent predictors of better 12-months survival in DC. CONCLUSION: Q-SPECT/CT (%QLU) is a novel non-invasive, diagnostic, prognostic, and theragnostic marker of liver reserve and its functions in cirrhosis patients. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT02451033 and NCT03415698. Frontiers Media S.A. 2023-03-22 /pmc/articles/PMC10073445/ /pubmed/37035316 http://dx.doi.org/10.3389/fmed.2023.1118531 Text en Copyright © 2023 Kaur, Verma, Singh, Kumar, Kumari, De, Sharma and Singh. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Kaur, Amritjyot Verma, Nipun Singh, Baljinder Kumar, Ajay Kumari, Sunita De, Arka Sharma, Ratti Ram Singh, Virendra Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis |
title | Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis |
title_full | Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis |
title_fullStr | Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis |
title_full_unstemmed | Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis |
title_short | Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis |
title_sort | quantitative liver spect/ct is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073445/ https://www.ncbi.nlm.nih.gov/pubmed/37035316 http://dx.doi.org/10.3389/fmed.2023.1118531 |
work_keys_str_mv | AT kauramritjyot quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis AT vermanipun quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis AT singhbaljinder quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis AT kumarajay quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis AT kumarisunita quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis AT dearka quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis AT sharmarattiram quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis AT singhvirendra quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis |